# National Institute of Allergy and Infectious Diseases (NIAID): Phase 3 study closed enrollment, 5832 enrolled (Tuberculosis, MDR)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| Study | Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients |
| NCT ID | NCT03568383 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Tuberculosis, MDR |
| Intervention types | drug, dietary supplement |
| Target enrollment | 5832 |
| Site countries | Botswana, Brazil, Haiti, India, Kenya, Peru, Philippines, South Africa, Tanzania, Thailand, Uganda, Vietnam |
| Posted | 2018-06-26 |
| Planned start | 2019-06-03 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 5832 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03568383). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.